Evonik is set to expand its 3D-printable biomaterials portfolio for medical technology with the introduction of new VESTAKEEP iC4800 3DF osteoconductive PEEK filament.
The new PEEK filament for 3D-printable implants is a biomaterial from Evonik’s VESTAKEEP Fusion product line, which was launched in 2020.
VESTAKEEP iC4800 3DF improves fusion between bone and implants.
The PEEK filament, with a diameter of 1.75mm, can be processed in common extrusion-based 3D printing technologies, such as fused filament fabrication (FFF).
With good biocompatibility and biostability, the polymer features improved osteoconductive properties.
The osteoconductivity of VESTAKEEP iC4800 3DF was achieved through the use of biphasic calcium phosphate (BCP), a functional special additive.
The additive accelerates patient recovery by allowing bone cells to adhere to implants more quickly.
VESTAKEEP iC4800 3DF has been specifically designed to ensure that the functional additives are placed directly on the surface of the 3D printed implant, eliminating additional post-processing steps.
Evonik medical systems head Marc Knebel said: “No other application field showcases more the classic advantages of 3D printing, such as individualisation or design freedom, than medical technology.
“Since the product launch of the first PEEK filament a good three years ago, we have been expanding the possibilities of modern medical technology in the individual treatment of patients using additive manufacturing by constantly developing new innovative biomaterials.”
In 2019, the company signed a long-term agreement with BellaSeno, a German additive manufacturing start-up, for the development of an innovative breast implant technology.
Evonik’s portfolio also includes VESTAKEEP Care M40 3DF, VESTAKEEP i4 3DF and the RESOMER line of bioresorbable filaments, powders and granules for implantable medical devices.